Wei Wei Commission: The patent price of foreign pharmaceutical companies is inflated

In recent days, he has introduced new reforms such as drug price reform and reform of public hospitals. Sun Zhigang, deputy director of the National Health and Family Planning Commission, stressed in his latest statement: “Prices of patented drugs and exclusive production drugs that China currently buys are generally high, and we hope to Through negotiation, we will use huge market demand in exchange for a relatively low and reasonable price."

Sun Zhigang revealed that patented medicines and exclusively produced medicines will implement the negotiation procurement model, with provinces as the units for negotiations, or provinces joining together to negotiate, and even the government negotiating on a certain species. “This practice is also common in the international community. When I visited Australia and New Zealand last month, I discovered that the local government came forward to negotiate the patent medicine of foreign drug companies, and then lowered the price. Now we have to establish A multi-participatory, open and transparent negotiation mechanism allows the price of proprietary drugs and exclusive drugs to fall within a reasonable range."

Some industry analysts worry that in the process of marketization of drug prices, if the price negotiation mechanism for patented drugs and exclusive drugs does not keep pace, it is likely that these "noble drugs" will continue to rise.

In fact, not long ago, the National Health and Family Planning Commission had released the export trend. This year, the drug price negotiation will select several varieties that people are more concerned about, such as some patented medicines, etc., to establish a negotiation mechanism, a negotiation platform, and finally to form rules. It is imperative to lower some of the high drug prices. A relevant person in charge of a foreign-funded drug company, who declined to be named, frankly stated that the price negotiations may involve various aspects such as the health department, the National Development and Reform Commission, the social security department, and local drug bidding offices. The negotiation mechanism will also be more complicated, so it is difficult to predict the time. And the impact on companies, but companies will always pay close attention to this.